Immune tolerance

搜索文档
Barinthus Biotherapeutics (BRNS) Earnings Call Presentation
2025-07-07 16:32
现金流与股本 - Barinthus Bio的现金余额为1.006亿美元,预计现金流可持续到2027年[5] - 截至2025年5月1日,普通股流通股数为4040万股[5] - 截至2025年3月31日,公司现金及现金等价物为1.006亿美元,且无债务或未偿还的认股权证[92] 临床试验与研发进展 - VTP-1000针对乳糜泻的临床试验正在进行中,预计在2025年第三季度发布单次递增剂量的数据[24] - VTP-1000旨在通过减少效应T细胞并增加调节性T细胞来诱导对麸质的耐受性[32] - VTP-1000的设计包括20纳米的麸质衍生肽抗原和mTOR抑制剂,采用自组装纳米颗粒形式[34] - VTP-1000在小鼠模型中显示出改善调节性T细胞与效应T细胞比率的潜力[20] - VTP-1000的临床试验设计包括单次递增剂量(N=18)和多次递增剂量(N=24)[36] - VTP-1000在预临床数据中显示出降低IL-2及其他炎症细胞因子的能力[46] - 预计2025年第三季度将发布VTP-1000(针对乳糜泻)的第一阶段单次递增剂量数据[92] HBV治疗进展 - VTP-300在HBV003试验中,组1和组2的参与者中分别有31.8%和34.8%在第169天达到了超过1 log HBsAg的下降[77] - 在HBV003试验中,71%的参与者符合停止NUC治疗的标准[78] - VTP-300设计用于克服T细胞耗竭,诱导高效HBV特异性效应T细胞以控制疾病[64] - VTP-300的临床试验显示,参与者在第29天后HBsAg水平下降,且这种下降在第169天时得以维持[78] - 目前全球约有2.54亿人感染HBV,每年新感染人数约为120万[60] - 现有HBV治疗方法的治愈率低于10%[60] - VTP-300的目标是通过刺激宿主免疫系统反应来实现功能性治愈[66] - 在IM-PROVE II试验中,接受Imdusiran、VTP-300和LDN的参与者中有25%达到了功能性治愈[89] 市场需求与患者情况 - 全球约1%的人口(约8000万人)患有乳糜泻,其中约60%的患者无法严格遵循无麸质饮食[27] - 约20%的乳糜泻患者对现有FDA或EMA批准的治疗无反应,约1600万人仍然有症状[27]
Barinthus Biotherapeutics plc (BRNS) Conference Transcript
2025-06-11 00:00
Barinthus Biotherapeutics plc (BRNS) Conference June 10, 2025 11:00 AM ET Speaker0 Good day, and welcome to q two investor summit virtual. We appreciate your participation in today's virtual event. Up next, we are pleased to introduce Parentus Biotherapeutics. If you would like to ask a question during the webcast, you may click the q and a icon button on the right side of your screen. Please type your question into the box and click send to submit it. At this time, it is my pleasure to hand over the sessio ...
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
Globenewswire· 2025-05-07 20:00
OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended March 31, 2025 and provided an overview of the Company's corporate developments. "2025 has started with a strategic focus on immunological and inflammatory dis ...